Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Massimo Puoti and Alessio Aghemo.
Massimo Puoti
Connection Strength
0.254
Alessio Aghemo
  1. Italian association for the study of the liver position statement on SARS-CoV2 vaccination. Dig Liver Dis. 2021 06; 53(6):677-681.
    View in: PubMed
    Score: 0.059
  2. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure. J Hepatol. 2019 12; 71(6):1106-1115.
    View in: PubMed
    Score: 0.052
  3. Real life experiences in HCV management in 2018. Expert Rev Anti Infect Ther. 2019 02; 17(2):117-128.
    View in: PubMed
    Score: 0.050
  4. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. Infection. 2018 Oct; 46(5):607-615.
    View in: PubMed
    Score: 0.048
  5. Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. Lancet Gastroenterol Hepatol. 2017 06; 2(6):427-434.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.